Oral application of Chinese herbal medicine for allergic rhinitis: A systematic review and meta‐analysis of randomized controlled trials

Chen

Int Arch Allergy Immunol

et al. 2023

Introduction: As one of the most common allergic diseases, allergic rhinitis (AR) has attracted wide attention all over the world. More appropriate treatment of AR should be explored thoroughly. In recent years, traditional Chinese medicine has attracted more attention in AR treatment. As a classical Chinese medicine prescription, Xiaoqinglong decoction (XQLD) has been commonly used in treating AR. Even though its therapeutic effect on AR has been clinically confirmed, more molecular mechanism remains to be further investigated. Our research aimed to investigate the therapeutic mechanism of XQLD for AR management. Methods: The study was evaluated in an ovalbumin sensitized mouse model and liquid chromatography-mass spectrometry was adopted to test the stability of XQLD’s effective components. Results: The results confirmed the stability and safety of the effective components of XQLD. XQLD significantly downregulated the expression of HDACs (HDAC1, HDAC3, and HDAC4) and Th2 inflammatory factors (IL4, IL5, and IL13) in AR mice. XQLD and the HDAC inhibitor JNJ-26481585 promoted the expression of epithelial tight junction proteins (claudin-1 and ZO-1) and decreased the expression of mucins (Muc5ac and Muc5b) in the nasal mucosa of AR mice. Conclusions: In conclusion, our findings present the beneficial effects of XQLD on AR and recovery of the nasal epithelium. We also identify the decreased HDAC as a potential target of XQLD for AR treatment. This study provides an important experimental proof for elucidating the therapeutic mechanism of XQLD.

Section: Discussionmentioning

confidence: 99%

HDAC Downregulation of Xiaoqinglong Decoction in the Treatment of Allergic Rhinitis

Chen

Int Arch Allergy Immunol

et al. 2023

“…Natural products have become a research hotspot for AR therapy because of their abundant sources, low prices, and few adverse reactions. With the development of research technology, the active ingredients in natural products and the mechanisms of their therapeutic action have been gradually elucidated (Li et al, 2021). They have clear advantages for the treatment of allergic diseases and broad prospects for application.…”

Section: Discussionmentioning

confidence: 99%

Anti‐inflammatory effect of dictamnine on allergic rhinitis via suppression of the LYN kinase‐mediated molecular signaling pathway during mast cell activation

Zhang

Wang

et al. 2023

Phytotherapy Research

Mast cells (MCs) are important therapeutic targets for allergic diseases. High‐affinity immunoglobulin E (IgE) Fc receptors (FcεRI) trigger abnormal activation of MCs. Allergic rhinitis (AR) is an IgE‐mediated antigen inhalation reaction that occurs in the nasal mucosa. MC aggravation and dysfunction were observed during the early stages of AR pathogenesis. Herb‐derived dictamnine exhibits anti‐inflammatory effects. Here, we investigated the pharmacological effects of herb‐derived dictamnine on IgE‐induced activation of MCs and an ovalbumin (OVA)‐induced murine AR model. The results indicated that dictamnine attenuated OVA‐induced local allergic reactions and reduced body temperature in OVA‐challenged mice with active systemic anaphylaxis. Additionally, dictamnine decreased the frequency of nasal rubbing and sneezing in an OVA‐induced murine AR model. Moreover, dictamnine inhibited FcεRI‐activated MC activation in a dose‐dependent manner without causing cytotoxicity, reduced the activation of the tyrosine kinase LYN in LAD2 cells, and downregulated the phosphorylation of PLCγ1, IP3R, PKC, Erk1/2, and Akt, which are downstream of LYN. In conclusion, dictamnine suppressed the OVA‐stimulated murine model of AR and activated IgE‐induced MCs via the LYN kinase‐mediated molecular signaling pathway, suggesting that dictamnine may be a promising treatment for AR.

“…For this reason, an increasing interest in herbal medicines that contain several natural compounds and have minimal or no undesirable side effects for treating various diseases is reported worldwide [16,17]. Herbal medicines also have a long history of beneficial effects in the alleviation of AR symptoms [18]. Herbal medicines such as Flos magnolia, Angelicae dahuricae, Astragalus, Xanthii fructus, and Asarum has been traditionally used for rhinitis treatments, and it is also used in rhinitis treatment these days [19].…”

Section: Introductionmentioning

confidence: 99%

Abies holophylla Leaf Essential Oil Alleviates Allergic Rhinitis Based on Network Pharmacology

et al. 2023

Abies holophylla is an evergreen coniferous species that has been widely used for treating pulmonary diseases and colds. Previous research has demonstrated the anti-inflammatory effect of Abies species and the anti-asthmatic activities of Abies holophylla leaf essential oil (AEO). As asthma and allergic rhinitis (AR) share pathophysiology and pharmacotherapeutic interventions, AEO inhalation can also ameliorate upper respiratory allergic diseases. This study explored the protective effects of AEO on AR with network pharmacological pathway prediction. The potential target pathways of AEO were analyzed by a network pharmacological approach. The BALB/c mice were sensitized by ovalbumin (OVA) and 10 μm particular matter (PM10) to induce allergic rhinitis. Aerosolized AEO 0.0003% and 0.03% were delivered by nebulizer for 5 min a day, 3 times a week for 7 weeks. Nasal symptoms (sneezing and rubbing), histopathological changes in nasal tissues, serum IgE, and zonula occludens-1 (ZO-1) expressions on nasal tissues were analyzed. After AR induction with OVA+PM10 and inhalation of AEO 0.0003% and 0.03% treatment, AEO significantly decreased allergic symptoms (sneezing and rubbing), hyperplasia of nasal epithelial thickness, goblet cell counts, and serum IgE level. The network analysis demonstrated that the possible molecular mechanism of AEO is highly associated with the IL-17 signaling pathway and tight junction. The target pathway of AEO was investigated in RPMI 2650 nasal epithelial cells. Treatment of AEO on PM10-treated nasal epithelial cells significantly reduced the production of inflammatory mediators related to the IL-17 signaling pathway, NF-κB, and the MAPK signaling pathway and prevented the reduction in TJ-related factors. When taken together, AEO inhalation may be considered as a potential treatment for AR by alleviating nasal inflammation and recovering the tight junction.